首页> 外文期刊>Drug Design, Development and Therapy >The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer
【24h】

The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer

机译:原发性非小细胞肺癌T淋巴细胞上多种免疫抑制受体的共表达

获取原文
           

摘要

Non-small-cell lung cancer (NSCLC) is a common disease threatening the health of humankind. It has a low survival rate and a poor prognosis. Under normal circumstances, tumor infiltrating lymphocytes (TILs) play the main role in the antitumor process, but studies in recent years have found that NSCLC is capable of releasing various immunosuppressive -factors, inducing the TILs to exhibit high expression of immune inhibitory receptors and relevant immunosuppressive factors. They can not only activate their own signal pathways but also block those of TILs, which causes inefficiency of tumor destruction. Researchers have now developed targeted drugs that specifically bind to immunosuppression receptors. By blocking signal transmission of immune inhibitory receptors, restraint on T lymphocytes can be released to recover antitumor role. Further research and understanding of the immunosuppression signal pathways of NSCLC are of significant importance to promote the development of immune-targeted drugs and the formulation of new treatment plans. This paper summarizes the immunosuppressive mechanisms of multiple important and newly discovered immune inhibitory receptors on T lymphocytes and immunosuppressive factors released by NSCLC cells, and their influence on patients’ survival rate and prognosis. Further laboratory and clinical studies on immune-targeted drugs for primary NSCLC are needed to provide more evidence.
机译:非小细胞肺癌(NSCLC)是威胁人类健康的常见疾病。生存率低,预后差。在正常情况下,肿瘤浸润淋巴细胞(TILs)在抗肿瘤过程中起主要作用,但近年来的研究发现NSCLC能够释放各种免疫抑制因子,诱导TILs表现出高表达的免疫抑制受体,并与之相关。免疫抑制因子。它们不仅可以激活自己的信号通路,而且可以阻断TIL的信号通路,从而导致肿瘤破坏效率低下。现在,研究人员已经开发了与免疫抑制受体特异性结合的靶向药物。通过阻断免疫抑制受体的信号传递,可以释放对T淋巴细胞的限制,以恢复抗肿瘤作用。进一步研究和了解NSCLC的免疫抑制信号通路对促进免疫靶向药物的开发和制定新的治疗计划具有重要意义。本文总结了多种重要的新发现的T淋巴细胞免疫抑制受体的免疫抑制机制以及NSCLC细胞释放的免疫抑制因子,以及它们对患者存活率和预后的影响。需要对原发性非小细胞肺癌的免疫靶向药物进行进一步的实验室和临床研究,以提供更多证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号